These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 32162818)

  • 1. Access to Novel Drugs for Non-Small Cell Lung Cancer in Central and Southeastern Europe: A Central European Cooperative Oncology Group Analysis.
    Cufer T; Ciuleanu TE; Berzinec P; Galffy G; Jakopovic M; Jassem J; Jovanovic D; Mihaylova Z; Ostoros G; Thallinger C; Zemanova M; Zielinski C
    Oncologist; 2020 Mar; 25(3):e598-e601. PubMed ID: 32162818
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Access to novel cancer medicines in four countries in Central and Eastern Europe in relation to clinical benefit.
    Hofmarcher T; Szilagyiova P; Gustafsson A; Dolezal T; Rutkowski P; Baxter C; Karamousouli E
    ESMO Open; 2023 Aug; 8(4):101593. PubMed ID: 37413761
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-Small Cell Lung Cancer in Countries of Central and Southeastern Europe: Diagnostic Procedures and Treatment Reimbursement Surveyed by the Central European Cooperative Oncology Group.
    Ryska A; Buiga R; Fakirova A; Kern I; Olszewski W; Plank L; Seiwerth S; Toth E; Zivka E; Thallinger C; Zielinski C; Brcic L
    Oncologist; 2018 Dec; 23(12):e152-e158. PubMed ID: 30076278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Time to access to novel anticancer drugs and the correlation with ESMO-Magnitude of Clinical Benefit Scale in Slovenia.
    Janzic U; Knez L; Janzic A; Cufer T
    Expert Rev Pharmacoecon Outcomes Res; 2019 Dec; 19(6):717-723. PubMed ID: 31826655
    [No Abstract]   [Full Text] [Related]  

  • 5. The European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) applied to pivotal phase III randomized-controlled trials of tyrosine kinase inhibitors in first-line for advanced non-small cell lung cancer with activating epidermal growth factor receptor mutations.
    Giuliani J; Remo A; Bonetti A
    Expert Rev Pharmacoecon Outcomes Res; 2017 Feb; 17(1):5-8. PubMed ID: 27830967
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The ESMO-Magnitude of Clinical Benefit Scale for novel oncology drugs: correspondence with three years of reimbursement decisions in Israel.
    Hammerman A; Greenberg-Dotan S; Feldhamer I; Birnbaum Y; Cherny NI
    Expert Rev Pharmacoecon Outcomes Res; 2018 Feb; 18(1):119-122. PubMed ID: 28617621
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of adjuvant chemotherapy (CT) and radiotherapy (RT) in incompletely resected (R1) early stage Non-Small Cell Lung Cancer (NSCLC): a European survey conducted by the European Society for Medical Oncology (ESMO) young oncologists committee.
    Califano R; Karamouzis MV; Banerjee S; de Azambuja E; Guarneri V; Hutka M; Jordan K; Kamposioras K; Martinelli E; Corral J; Postel-Vinay S; Preusser M; Porcu L; Torri V
    Lung Cancer; 2014 Jul; 85(1):74-80. PubMed ID: 24746176
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Access to innovative medicines for metastatic melanoma worldwide: Melanoma World Society and European Association of Dermato-oncology survey in 34 countries.
    Kandolf Sekulovic L; Guo J; Agarwala S; Hauschild A; McArthur G; Cinat G; Wainstein A; Caglevic C; Lorigan P; Gogas H; Alvarez M; Duncombe R; Lebbe C; Peris K; Rutkowski P; Stratigos A; Forsea AM; De La Cruz Merino L; Kukushkina M; Dummer R; Hoeller C; Gorry C; Bastholt L; Herceg D; Neyns B; Vieira R; Arenberger P; Bylaite-Bucinskiene M; Babovic N; Banjin M; Putnik K; Todorovic V; Kirov K; Ocvirk J; Zhukavets A; Ymeri A; Stojkovski I; Garbe C
    Eur J Cancer; 2018 Nov; 104():201-209. PubMed ID: 30388700
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HTA and Reimbursement Status of Metastatic Hormone‑Sensitive Prostate Cancer, Non-Metastatic Castration-Resistant Prostate Cancer, and Metastatic Castration-Resistant Prostate Cancer Treatments in Europe: A Patient Access Landscape Review.
    Bencina G; Petrova E; Sönmez D; Matos Pereira S; Dimitriadis I; Salomonsson S
    J Health Econ Outcomes Res; 2023; 10(1):102-110. PubMed ID: 37366384
    [No Abstract]   [Full Text] [Related]  

  • 10. Achieving equal and timely access to innovative anticancer drugs in the European Union (EU): summary of a multidisciplinary CECOG-driven roundtable discussion with a focus on Eastern and South-Eastern EU countries.
    Wilking N; Bucsics A; Kandolf Sekulovic L; Kobelt G; Laslop A; Makaroff L; Roediger A; Zielinski C
    ESMO Open; 2019; 4(6):e000550. PubMed ID: 31798977
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessing the benefit of cancer drugs approved by the European Medicines Agency using the European Society for Medical Oncology Magnitude of Clinical Benefit Scale over time.
    Thomson S; Witzke N; Gyawali B; Delos Santos S; Udayakumar S; Cardone C; Cheung MC; Chan KKW
    Eur J Cancer; 2021 Jun; 150():203-210. PubMed ID: 33932727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical aspects of reimbursement policies for orphan drugs in Central and Eastern European countries.
    Jakubowski S; Kawalec P; Holko P; Kowalska-Bobko I; Kamusheva M; Petrova G; Draganić P; Fuksa L; Männik A; Ispán F; Briedis V; Bianchi I; Paveliu MS; Tesar T
    Front Pharmacol; 2024; 15():1369178. PubMed ID: 38523639
    [No Abstract]   [Full Text] [Related]  

  • 13. Analyzing the clinical benefit of newer therapies for advanced or metastatic non-small-cell lung cancer: application of the ESMO-magnitude of clinical benefit scale v1.1.
    García-Fumero R; Fernández-López C; Calleja-Hernández MÁ; Expósito-Hernández J
    Acta Oncol; 2021 Sep; 60(9):1225-1232. PubMed ID: 34184595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NSCLC molecular testing in Central and Eastern European countries.
    Ryska A; Berzinec P; Brcic L; Cufer T; Dziadziuszko R; Gottfried M; Kovalszky I; Olszewski W; Oz B; Plank L; Timar J
    BMC Cancer; 2018 Mar; 18(1):269. PubMed ID: 29523116
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of changes in the clinical benefits of oncology drugs over time following reimbursement using the ASCO-VF and the ESMO-MCBS.
    Yoon NR; Na YJ; Lee JH; Song I; Lee EK; Park MH
    J Cancer Res Clin Oncol; 2024 Mar; 150(3):113. PubMed ID: 38436796
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Examining the association between oncology drug clinical benefit and the time to public reimbursement.
    Thomson S; Everest L; Witzke N; Jiao T; Delos Santos S; Nguyen V; Cheung MC; Chan KKW
    Cancer Med; 2022 Jan; 11(2):380-391. PubMed ID: 34850587
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cancer Control in Central and Eastern Europe: Current Situation and Recommendations for Improvement.
    Vrdoljak E; Bodoky G; Jassem J; Popescu RA; Mardiak J; Pirker R; Čufer T; Bešlija S; Eniu A; Todorović V; Kubáčková K; Kurteva G; Tomašević Z; Sallaku A; Smichkoska S; Bajić Ž; Šikić BI
    Oncologist; 2016 Oct; 21(10):1183-1190. PubMed ID: 27401890
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reimbursement Legislations and Decision Making for Orphan Drugs in Central and Eastern European Countries.
    Malinowski KP; Kawalec P; Trąbka W; Czech M; Petrova G; Manova M; Savova A; Draganić P; Vostalová L; Slabý J; Männik A; Márky K; Rugaja Z; Gulbinovic J; Tesar T; Paveliu MS
    Front Pharmacol; 2019; 10():487. PubMed ID: 31139080
    [TBL] [Abstract][Full Text] [Related]  

  • 19. More than 5000 patients with metastatic melanoma in Europe per year do not have access to recommended first-line innovative treatments.
    Kandolf Sekulovic L; Peris K; Hauschild A; Stratigos A; Grob JJ; Nathan P; Dummer R; Forsea AM; Hoeller C; Gogas H; Demidov L; Lebbe C; Blank C; Olah J; Bastholt L; Herceg D; Neyns B; Vieira R; Hansson J; Rutkowski P; Krajsova I; Bylaite-Bucinskiene M; Zalaudek I; Maric-Brozic J; Babovic N; Banjin M; Putnik K; Weinlich G; Todorovic V; Kirov K; Ocvirk J; Zhukavets A; Kukushkina M; De La Cruz Merino L; Ymeri A; Risteski M; Garbe C
    Eur J Cancer; 2017 Apr; 75():313-322. PubMed ID: 28264791
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune checkpoint inhibitors for the treatment of non-small cell lung cancer: A comparison of the regulatory approvals in Europe and the United States.
    Zaim R; Redekop K; Uyl-de Groot CA
    J Cancer Policy; 2022 Sep; 33():100346. PubMed ID: 35779788
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.